Anna Gleason

Segment Producer @CNBCFastMoney, all things biopharma / engagements ≠ endorsements

[CNBC's Fast Money @CNBCFastMoney]

"Positive messaging on Iran would go a long way," says @shehzadhqazi of @ChinaBeigeBook on potential outcomes from the Trump-Xi meeting.

https://t.co/kFBKPNy2rt

[Leah Goodridge @leahfrombklyn]

Do you have an elderly or disabled neighbor in NYC?

Be a good neighbor and let them know about the free air conditioner program.

If they earn $3473 or less a month, NYC will cover the costs of an A/C. Remember…last summer we had 95 degree weather. Look out for them

[CNBC's Fast Money @CNBCFastMoney]

"We have potentially the best in class profile based on efficacy, safety, manufacturing and one of the futures I think for this field: combinability," says @StructureTx CEO Ray Stevens.

He discusses $GPCR's portfolio as the company nears $6B in value.
https://t.co/FuHHXMCByc

[CNBC's Fast Money @CNBCFastMoney]

Novo Nordisk's Wegovy pill is launching direct-to-consumer with @ro

CEO @ZReitano breaks down what the launch means for patients, his company's partnership with $NVO, and more https://t.co/6Zo1l3z8k8

[CNBC's Fast Money @CNBCFastMoney]

Defense innovation and space are emerging areas in the private side, says @alumniventures's Laura Rippy.

The VC investor also talks the rise of AI investing and the 2026 companies to watch.
https://t.co/sniWusND57

[CNBC's Fast Money @CNBCFastMoney]

Stay tuned for tomorrow's Fast Money Live! We can't wait🪩!

[CNBC's Fast Money @CNBCFastMoney]

What does #Bitcoin's breakdown mean for digital asset treasury companies like $MSTR and beyond?

@PanteraCapital's @Cosmo_Jiang digs into the numbers and the health of the crypto system https://t.co/zhOMmoBEk6

[CNBC's Fast Money @CNBCFastMoney]

20% upside for tech in 2026?

That's Wedbush's @DivesTech's bull case! His views on the AI trade, $NVDA's latest bet, the market's biggest risks, and more https://t.co/BFfgQoGPEq

[CNBC's Fast Money @CNBCFastMoney]

Oracle and CoreWeave represent the bad behavior in the AI buildout, warns @gilluria of @DADavidsonCo

He says $MSFT $AMZN $GOOGL are better positioned due to their tremendous cash flow.

$ORCL $CRWV
https://t.co/iG6Ta19x6U

[CNBC's Fast Money @CNBCFastMoney]

Who's the biggest winner in the biotech space?

Leerink's David Risinger just upgraded $LLY to outperform and stuck a $1,104 price target on the GLP-1 giant. He lays out why he's getting bullish on M&A prospects and beyond https://t.co/PYBFyagjCe

[CNBC's Fast Money @CNBCFastMoney]

A biotech breakout filled with superlatives!

$IBB having its best day since may, $LLY hitting a fresh record high, and more...

@TimSeymour, @GuyAdami, @TimSeymour, and Dan Nathan break down the action https://t.co/fNSiMoAwye

[CNBC's Fast Money @CNBCFastMoney]

Insmed is nearly on pace with Palantir for gains this year - nearly tripling!

What are the next catalysts for the high-flyer in the gene therapy space and beyond? @Insmed CEO Will Lewis breaks it down https://t.co/ICMy7ZRVLr

[CNBC's Fast Money @CNBCFastMoney]

Biopharma companies are betting big on drugs that treat MASH, a serious liver disease linked to obesity and metabolic issues.

@MadrigalPharma's MASH drug was the first to clear the FDA. $MDGL CEO Bill Sibold lays out the outlook for the space:

https://t.co/JpXu6M6trz

[CNBC's Fast Money @CNBCFastMoney]

$KVUE recovering some of Monday's losses after hours after the Trump administration linked its Tylenol product to autism

Dr. @ashishkjha says health professionals will continue to push back on that claim, and breaks down what's next for the industry https://t.co/SxbELvQwF3

[CNBC's Fast Money @CNBCFastMoney]

A new disruptor in the weight loss space?

@SignosHealth nabbing FDA approval for the first-ever glucose monitoring system for weight management. CEO @sharamfm discusses the use case for wearable health tech amid sky-high demand for GLP-1 drugs:
https://t.co/4PlFyq1TWf

[CNBC's Fast Money @CNBCFastMoney]

"If you don't have innovation, you can't raise price..."

Needham's Laura Martin breaks down what she calls $AAPL's disappointing iPhone 17 reveal, pricing problems, and lackluster AI capabilities for new hardware https://t.co/77YkKQbjWB

[CNBC's Fast Money @CNBCFastMoney]

How could RFK Jr.’s autism report ripple through pharma and public health?

Fmr. FDA Commissioner @ScottGottliebMD assesses the risks to pediatric vaccine schedules. He also talks new Covid shot guidelines and the HHS secretary's Senate hearing this week.
https://t.co/OzRvGZl0c0

[CNBC's Fast Money @CNBCFastMoney]

"We need a confession..."

@Jefferies' Randy Konik, Wall Street's biggest $LULU bear, reacts to the sportswear company's post-earnings plunge and predicts when the stock may finally bottom out

https://t.co/8Sho37poFk

[CNBC's Fast Money @CNBCFastMoney]

"The regulatory bark is much worse than the bite..."

@deepwatermgmt's @munster_gene weighs in on $GOOGL's huge antirust win and what it means for names like $META and the rest of big tech

https://t.co/3faqoyvaWu

[CNBC's Fast Money @CNBCFastMoney]

Great news for $GOOGL

Alphabet hitting an all-time high after hours as a judge rules it won't have to sell off Chrome or any other assets...

Fmr. Assistant Attorney General @JKBustertruster shares his take on the ruling and what it means for big tech

https://t.co/zuTrpZ14Vq